These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 10385666

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK.
    N Engl J Med; 1998 Nov 19; 339(21):1485-92. PubMed ID: 9819446
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.
    Reedy DW, Loo AT, Levine RA.
    Dig Dis Sci; 1998 Sep 19; 43(9):2156-9. PubMed ID: 9753286
    [Abstract] [Full Text] [Related]

  • 26. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F, De Diego A, Casado M, Matilla A, Bañares R, García-Durán F, Salcedo M, Cos E, Clemente G.
    Rev Esp Enferm Dig; 1996 Sep 19; 88(9):609-15. PubMed ID: 8962775
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM, Tong MJ, McHutchison JG, Russell J, Schmid P, Conrad A.
    J Interferon Cytokine Res; 1998 Feb 19; 18(2):75-80. PubMed ID: 9506457
    [Abstract] [Full Text] [Related]

  • 29. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells.
    Schmidt WN, Wu P, Brashear D, Klinzman D, Phillips MJ, LaBrecque DR, Stapleton JT.
    Hepatology; 1998 Oct 19; 28(4):1110-6. PubMed ID: 9755250
    [Abstract] [Full Text] [Related]

  • 30. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
    Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A.
    Hepatology; 1997 Dec 19; 26(6):1640-5. PubMed ID: 9398010
    [Abstract] [Full Text] [Related]

  • 31. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy.
    Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Nakamura I, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kobayashi M, Kumada H.
    J Gastroenterol; 1999 Oct 19; 34(5):594-9. PubMed ID: 10535487
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, Chamuleau RA, Michielsen PP, Pirotte J, Hautekeete ML, Weber J, Bourgeois N, Hansen BE, Bronkhorst CM, ten Kate FJ, Heijtink RA, Fevery J, Schalm SW.
    J Hepatol; 1998 Jun 19; 28(6):951-9. PubMed ID: 9672169
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y, Tanaka E, Orii K, Rokuhara A, Ichijo T, Yoshizawa K, Kiyosawa K.
    J Gastroenterol Hepatol; 2000 Nov 19; 15(11):1292-7. PubMed ID: 11129224
    [Abstract] [Full Text] [Related]

  • 36. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group.
    Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D.
    J Viral Hepat; 1999 Mar 19; 6(2):145-50. PubMed ID: 10607226
    [Abstract] [Full Text] [Related]

  • 37. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, Unuma T, Okano K, Ikeda Y, Hirano M, Kawase T, Takano S, Matsumoto K, Ohashi Y, Omata M.
    Hepatology; 1999 May 19; 29(5):1573-80. PubMed ID: 10216145
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
    Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, Sanyal AJ, Mills AS, Garrett CT.
    Hepatology; 1997 Sep 19; 26(3):780-5. PubMed ID: 9303513
    [Abstract] [Full Text] [Related]

  • 40. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
    Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P.
    Am J Gastroenterol; 2003 May 19; 98(5):1150-4. PubMed ID: 12809841
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.